Abstract:Abstract Development of new drugs is of high interest for the field of cardiac and cardiovascular diseases, which are a dominant cause of death worldwide. Before being allowed to be used and distributed, every new potentially therapeutic compound must be strictly validated during preclinical and clinical trials. The preclinical studies usually involve the in vitro and in vivo evaluation. Due to the increasing reporting of discrepancy in drug effects in animal and humans and the requirement to reduce the number of animals used in research, improvement of in vitro models based on human cells is indispensable. Primary cardiac cells are difficult to access and maintain in cell culture for extensive experiments; therefore, the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) became an excellent alternative. This technology enables a production of high number of patient- and disease-specific cardiomyocytes and other cardiac cell types for a large-scale research. The drug effects can be extensively evaluated in the context of electrophysiological responses with a use of well-established tools, such as multielectrode array (MEA), patch clamp, or calcium ion oscillation measurements. Cardiotoxicity, which is a common reason for withdrawing drugs from marketing or rejection at final stages of clinical trials, can be easily verified with a use of hiPSC-CM model providing a prediction of human-specific responses and higher safety of clinical trials involving patient cohort. Abovementioned studies can be performed using two-dimensional cell culture providing a high-throughput and relatively lower costs. On the other hand, more complex structures, such as engineered heart tissue, organoids, or spheroids, frequently applied as co-culture systems, represent more physiological conditions and higher maturation rate of hiPSC-derived cells. Furthermore, heart-on-a-chip technology has recently become an increasingly popular tool, as it implements controllable culture conditions, application of various stimulations and continuous parameters read-out. This paper is an overview of possible use of cardiomyocytes and other cardiac cell types derived from hiPSC as in vitro models of heart in drug research area prepared on the basis of latest scientific reports and providing thorough discussion regarding their advantages and limitations.

Engineered platforms for mimicking cardiac development and drug screening

Engineering Cardiac Tissue for Advanced Heart‐on‐a‐chip Platforms

Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Biomimetic Cardiac Microsystems for Pathophysiological Studies and Drug Screens

Deciphering Congenital Heart Disease Using Human Induced Pluripotent Stem Cells

A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling

Current advances in human-induced pluripotent stem cell-based models and therapeutic approaches for congenital heart disease

Cardiac Organoids: A 3D Technology for Modeling Heart Development and Disease

Unveiling New Horizons in Heart Research: the Promise of Multi-Chamber Cardiac Organoids

Differentiation of Pluripotent Stem Cells for Disease Modeling: Learning from Heart Development

Design and fabrication of an integrated heart-on-a-chip platform for construction of cardiac tissue from human iPSC-derived cardiomyocytes and in situ evaluation of physiological function

Strategies for Constructing Pluripotent Stem Cell- and Progenitor Cell-Derived Three-Dimensional Cardiac Micro-Tissues.

Engineered human cardiac tissues for modeling heart diseases

Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications

Human pluripotent stem cell-based models of heart development and disease

Bioengineering Strategies to Create 3D Cardiac Constructs from Human Induced Pluripotent Stem Cells

A patterned human primitive heart organoid model generated by pluripotent stem cell self-organization

Organ-on-a-chip technology: a novel approach to investigate cardiovascular diseases

Cardiac Organoids: A 3D Technology for Disease Modeling and Drug Screening.

New Modalities of 3D Pluripotent Stem Cell-Based Assays in Cardiovascular Toxicity